Petropoulos, Christos J.

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 1,324

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng, S., Phillips, D. J., White, T., Sayal, H., Aley, P. K., Bibi, S., Dold, C., Fuskova, M., Gilbert, S. C., Hirsch, I., et al. (2021) · Nature Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 1,163

Multiple early factors anticipate post-acute COVID-19 sequelae

Su, Y., Yuan, D., Chen, D. G., Ng, R. H., Wang, K., Choi, J., Li, S., Hong, S., Zhang, R., Xie, J., et al. (2022) · Cell

Long-Term Effects of COVID-19COVID-19 Clinical Research Studies

Cited by 1,156

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett, J. R., Belij-Rammerstorfer, S., Dold, C., Ewer, K. J., Folegatti, P. M., Gilbride, C., Halkerston, R., Hill, J., Jenkin, D., Stockdale, L., et al. (2021) · Nature Medicine

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 315

SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay

Peluso, M. J., Takahashi, S., Hakim, J., Kelly, J. D., Torres, L., Iyer, N. S., Turcios, K., Janson, O., Munter, S. E., Thanh, C., et al. (2021) · Science Advances

SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testing

Cited by 130